Literature DB >> 2909389

Chromatin reorganization during emergence of malignant Friend tumors: early changes in H2A and H2B variants and nucleosome repeat length.

K E Leonardson1, S B Levy.   

Abstract

Serial examination of five newly derived Friend murine tumors during early subcutaneous passages showed continuing changes in chromatin composition and structure over the first 10 to 20 passages followed by a period of stabilization over the subsequent 20 passages. These changes were reflected in a decrease in two major histone variants, H2A.1 and H2B.2, with a coordinate increase in histone variants, H2A.2 and H2B.1, and a changing nucleosome repeat length (NRL). The absolute values differed among the five tumors, but all five showed the same general direction of change. There was no obvious relationship among the NRL, H2A, and H2B histone variant values. A low H2A.1/H2A.2 ratio was found in Friend tumors of high malignant potential. Cell lines derived in vitro also showed directional changes in the H2A and H2B variants similar to those of their tumor cell parents, but with different kinetics. Our findings suggest that Friend tumor establishment is accompanied by an early period of chromatin reorganization marked by changes in several parameters of chromatin structure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2909389     DOI: 10.1016/0014-4827(89)90225-5

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  2 in total

1.  Chromatin changes in cell transformation: progressive unfolding of the higher-order structure during the evolution of rat hepatocyte nodules. A differential scanning calorimetry study.

Authors:  P Barboro; A Pasini; S Parodi; C Balbi; B Cavazza; C Allera; G Lazzarini; E Patrone
Journal:  Biophys J       Date:  1993-10       Impact factor: 4.033

Review 2.  Histone H2A.Z deregulation in prostate cancer. Cause or effect?

Authors:  Deanna Dryhurst; Juan Ausió
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.